Are you aware that more than 90% of the populace hosts genetic variances classified as “clinically actionable,” potentially influencing their response to pharmacotherapies? This eye-opening datum paves the way for PGx testing to significantly alter the landscape of both drug development and clinical trials1.
Pharmacogenomics testing, or PGx testing, heralds a departure from the customary hit-or-miss method towards a nuanced drug prescription strategy premised on individual genetic makeup. Its core function involves pinpointing the effects of genetic variances on the body’s handling of drugs, which could translate to enhanced therapeutic outcomes and fewer adverse drug events2. The challenges in operationalizing PGx, underscored by Assistant Professor Pawel Mroz, span regulatory complexities essential for its integration into standard clinical practices.
The CPIC’s crucial role in promulgating guidance for incorporating pharmacogenomic insights into nearly 200 FDA-endorsed drugs marks a significant milestone1. Concurrently, Mroz’s leadership in the Go4PGx initiative accentuates the critical import of PGx testing in clinical judgments, advocating for its systematic inclusion within the health sector. Noteworthy is a Minnesota study’s finding that 84% of its participants expressed readiness for undergoing PGx-informed personalized medical assessments, signifying a broad public acceptance of PGx-guided care1.
Introduction to Pharmacogenomics and PGx Testing
Pharmacogenomics, known as pharmacogenomics testing, explores the genetic drivers behind individuals’ diverse reactions to drugs. It delves into the genetic alterations impacting drug breakdown and utilization. An example is the variable effect genetic variants have on drug responses, seen in aspirin and cancer medications.
Definition and Scope of Pharmacogenomics
Pharmacogenomics testing examines genetic signatures influencing how drugs are processed, enabling tailored drug regimens. This precision allows for treatments customized to an individual’s genetic blueprint, enhancing therapeutic success and reducing adverse reactions. Its application encompasses a range of techniques, prominently DNA and genetic tests curating proper drug responses, establishing a foundation for precise medical care. Noteworthily, clinic referrals by 77% of PGx patients highlight the valuable role clinicians play in endorsing testing3. Clinical integration further bolsters pharmacogenomics, with initiatives such as Sanford Health’s offering extensive evaluations by PGx-trained professionals to bolster patient care3.
The History and Evolution of PGx Testing
The genesis of pharmacogenomics, propelled by the Human Genome Project’s exhaustive genetic analysis, has progressed through the in-depth evaluations of diverse genetic maps at institutions like the Mayo Clinic4. The field has seen clinical applications through the guidance of bodies like the Clinical Pharmacogenetics Implementation Consortium, which has facilitated tailored medicine guidelines for over a decade. This underpins efforts towards personalized healthcare. Institutions like Sanford have embraced PGx, with substantial testing among its patient population3.
The maturation of genetic analyses, encompassing advanced techniques like multiplex molecular testing and NGS, is pivotal for pharmacogenomics’ routine medical utilization. Institutions such as Sanford Health utilize extensive gene panels, evidencing the testing’s thoroughness3. Concurrently, the Mayo Clinic’s investigative studies focus on identifying relevant genetic mutations, enhancing cancer therapy personalization through pharmacogenomics insights4.
Pharmacogenomics’ practice is expanding, evident in projects like the RIGHT Study, enriching electronic records with pharmacogenomic insights for tailored treatment4. The breadth of pharmacogenomics adoption, as seen in Sanford Health’s extensive network, showcases its integration into varied and widespread medical settings. This points to its ongoing growth and application in refining medication responses through genetic understanding3.
The Science Behind PGx Testing
Pharmacogenomics (PGx) testing is engrossed in the meticulous analysis of genetic variants, particularly single nucleotide polymorphisms (SNPs). These variants significantly impact the metabolism of drugs, thereby affecting therapeutic efficacy and the incidence of adverse reactions. Such comprehensive evaluation at the genetic level allows for tailored medical interventions, enhancing patient care outcomes.
Genetic Variants and Drug Metabolism
Precise comprehension of genetic variants is critical in the customization of medication regimens. Notably, variants within genes such as CYP2C19, CYP2D6, and CYP2C9, pivotal in drug metabolism, are extensively scrutinized in PGx analyses. The comprehensive PGx panel implemented at institutions like Sanford Health integrates these vital genes, ameliorating the perils of inappropriate drug metabolism and bettering patient health prospects3.
Single Nucleotide Polymorphisms
Single nucleotide polymorphisms (SNPs) are paramount in delineating genetic variability in humans. These minute alterations in the DNA sequence can significantly influence the metabolism of pharmaceuticals. For example, specific SNPs modulate the enzymatic functionality crucial in drug processing, thereby affecting both the therapeutic and side effect profiles of medications5. The application of sophisticated genomic testing platforms in PGx testing ensures the meticulous detection of these SNPs, facilitating the prescription of individualized treatment strategies.
| Gene | Function | Impact |
|---|---|---|
| CYP2C19 | Drug Metabolism Enzyme | Influences the metabolism of drugs like clopidogrel |
| CYP2D6 | Drug Metabolism Enzyme | Affects processing of antidepressants, antipsychotics |
| IFNL3 | Drug Response | Associated with response to interferon-based hepatitis C therapy |
The Role of PGx Testing in Personalized Medicine
Pharmacogenomics (PGx) testing has emerged as a pivotal element in the realm of personalized medicine, empowering healthcare professionals to customize treatment plans according to the unique genetic makeup of each patient. This methodology allows for the tailored adjustment of drug regimens, maximizing therapeutic effects while curbing adverse reactions based on an individual’s genetic nuances6.
Individualized Drug Therapy
In the domain of individualized drug therapy, PGx testing shines by delving into genetic polymorphisms. It examines variances like 4G/5G PAI-1, crucial for foreseeing responses to treatments spanning from Type 2 diabetes to age-related macular degeneration7. Such precision permits clinicians to administer medications specifical to the patient, optimizing not only the effectiveness but the safety of medical regimens7.
Reducing Adverse Drug Reactions
The issue of adverse drug reactions stands as a prominent challenge in the medical field, influencing patient well-being and healthcare costs. PGx testing comes forth as a pioneering solution by uncovering genetic variations, facilitating the customization of medical prescriptions for a safer healthcare dimension6. Efficacy in the context of treating conditions like major depressive disorder underlies the invaluable role of pharmacogenetic methodologies7.
Improving Patient Outcomes
The potential enhancements in patient outcomes emanating from PGx testing are significant. Through the provision of bespoke treatment plans, efficacy and safety are vastly augmented. Here, the vital importance of comprehensive training for pharmacists in the deployment of PGx services surfaces, playing a critical role in the synergy to enhance patient results6. The initiation of preemptive clinical pharmacogenetics within US medical realms further enforces the pivotal role played by this personalized healthcare approach7.
Integration of PGx testing within clinical paradigms not only solidifies its standing as an indispensable aspect of personalized medicine but also signifies its potential to revolutionize healthcare practice by diminishing adverse drug reactions and fostering improved patient outcomes.
Implementation of PGx Testing in Clinical Settings
Success in the integration of PGx testing within clinical contexts is predicated on strict adherence to meticulously outlined clinical protocols, precision during sample acquisition, and exhaustive analytic assessment. The Clinical Pharmacogenetics Implementation Consortium (CPIC) serves as the pivotal architect in the formulation of these standards. Mastery and application of these guidelines are indispensable for the accurate assimilation and utilization of PGx testing findings in the operational landscape of healthcare establishments.
Clinical Guidelines and Standards
Integration within clinical trials demands unwavering conformity to nuanced clinical PGx standards with the objective of guaranteeing precision and dependability. At Sanford Health, for example, following extensive PGx panel testing that delves into genes such as CYP2C19 and CYP2D6, patients are privy to personalized directives embedded within their electronic health records, accentuating crucial drug-gene interactions3. Furthermore, trained clinical pharmacists undertake exhaustive clinical evaluations that stand as a cornerstone in the workflow3. The embrace of such comprehensive protocols underscores the pivotal role of clinical PGx guidelines in the provisioning of exact, patient-tailored healthcare.
Logistics of PGx Testing: Sample Collection and Analysis
The logistical underpinnings of PGx testing commence with meticulous specimen retrieval. Predominantly achieved through blood extraction or the collection of buccal mucosa samples, this process ensures the procurement of DNA of high quality, conducive to precise genetic scrutiny. An excess of 29,000 individuals have undergone PGx testing utilizing varied methodologies, signifying the extensiveness and systematization of its current execution3. The operation is heavily reliant on sophisticated informatics pathways, which transform these samples into actionable data, delineating patients’ pharmacological profiles, all in adherence to PGx tenets.
Reportedly, the interactions at Sanford Health’s PGx facility are distributed almost evenly between face-to-face and virtual encounters, showcasing the versatility and span of these interventions3. Complemented by educational initiatives, these services bolster the understanding of medical practitioners, directing efforts towards seamless integration of PGx clinical criteria into day-to-day casework. The strategy deployed by Sanford Health aptly illustrates how the implementation of PGx testing can transcend geographic limitations, covering an expansive area of nearly 250,000 square miles, housing 46 medical hubs and 222 clinical units3. This extensive infrastructure is designed to widen the public’s access to advanced PGx examination and individually tailored medical treatment, effectively setting a paradigm for the proliferation of precision medicine within varied clinical ecosystems.
Key Technologies Used in PGx Testing
Pharmacogenomics (PGx) Testing is underpinned by a suite of sophisticated technologies. These innovations meticulously assess the genetic variations governing drug reactions. Leveraging cutting-edge informatics, PGx augments the accuracy and scope of individualized medical treatments.
Next-Generation Sequencing
At the foundation of PGx testing is next-generation sequencing (NGS). This method conducts an exhaustive examination of the genome. By pinpointing a vast array of genetic alterations, significant for drug metabolism, NGS, specifically whole exome sequencing (WES) and whole genome sequencing (WGS), emerges as indispensable. It operates independent of variances, ensuring diagnostic inclusivity, albeit constrained by its economic implications and complexities in perhaps functionally elucidating these variances8. The costs associated with genomic technologies pose a significant barrier to the widespread application of NGS methodologies9.
Multiplex Genotyping
Multiplex genotyping complements NGS by furnishing detailed insights into specific genetic biomarkers invoked in drug metabolism. It incorporates an array of assays, such as PCR-based methodologies, bead-based immunoassays, microarrays, and MassArrays, enabling concurrent assessments of several genetic alterations8. This approach, concentrating on drug-metabolizing enzymes, transporters, and receptors, intensely boosts the exactitude and detection limits of PGx evaluations10. The implementation of automated technologies, exemplified by the SNPline Genotyping Automation from Biosearch Technologies, further elevates the speed and scalability of pharmacogenomics9.
“Translating genotype data from substantial biobank participants into actionable clinical insights underscores the promise of PGx testing in personalized healthcare,” remarks the Royal Dutch Pharmacists Association9.
PGx Testing in Drug Development
Pharmacogenomics, or PGx Testing, is reshaping the landscape of drug development, magnifying both efficacy and safety ratios. By delving into individual genetic makeup and its interaction with pharmaceuticals, the field pioneers a bespoke paradigm. This paradigm sharpens therapeutic precision, curbing adverse drug reactions, thus, heightening favorable patient outcomes.
Enhancing Drug Efficacy and Safety
In the domain of advanced oncology, around 60% of patients are prescribed medications interfacing with PGx markers11. Consequently, the mandate for PGx Testing is irrefutable, pivotal in fortifying drug safety protocols. Tragically, despite the availability of such molecular insights, over a thousand succumb to the inherent toxicity of chemotherapy annually, underpinning the indispensable role PGx plays in personalizing medication regimes11. Refined treatment strategies via PGx assessments culminate in tailored pharmaceutical regimens, accentuating patient safety strategically.
Streamlining Clinical Trials
The imperative of PGx Testing is not confined to patient care but extends its utility to expediting clinical trial dynamics. Through a meticulous examination of genetic nuances, patient cohorts are meticulously selected, thereby augmenting the identification of efficacious treatment modalities. This not only compresses the temporal and monetary investments in drug development but also fosters a dynamic edge in therapeutic innovation.
Despite the stride made in trial acceleration and treatment personalization, a crucial disparity permeates—predominantly homogenous participation distorting outcome universality11. Nonetheless, the strategic integration of PGx assays bears the promise of mitigating this variance, fostering a truer reflection of a diverse patient population, thus, enhancing clinical trial robustness.
Highlighting its seminal importance, the US FDA has meticulously mapped out PGx biomarkers, cementing a foundational resource in ensuring drug safety incarnated through PGx12. Furthermore, critical evaluation on its economic plausibility tips the balance in favor of adopting PGx, indicating substantial reductions in healthcare outlays resulting from precision-guided medication regimens12. These collective advancements not only refine the clinical trial enclave but also push the boundaries of individualized medicine, propositioning a future hinged on genetic profiling.
Challenges and Barriers to Implementing PGx Testing
The integration of pharmacogenomics (PGx) testing in healthcare settings represents a monumental challenge laden with regulatory and ethical dilemmas. These hurdles are foundational in ensuring patient welfare, the sanctity of their private information, and the underlying integrity of health systems. Critical to this discussion is the complexity in drafting comprehensive guidelines that confront the intricate nature of genetic information. Additionally, meticulous address of ethical quandaries, specifically those concerning patient data confidentiality and the necessity for informed consent, is imperative.
Regulatory and Ethical Concerns
Implementation of PGx testing intersects numerous regulatory prerequisites, presenting a formidable obstacle. Notably, the United Kingdom’s National Health Service (NHS) has set the milestone for PGx to become a standard component of its services by 2025, a goal shrouded in current underutilization within mental health domains13. The juxtaposition of personalized medicine’s promises against ethical imperatives – focusing on autonomy and privacy – demands intricate navigation.
Healthcare Provider Education and Training
Strategized healthcare education is indispensable for the seamless assimilation of PGx analysis into medical practice. In the context of psychiatry, PGx holds the potential to revolutionize therapeutic efficacy through personalized prescription methodologies13. Herein lies the mandate for healthcare personnel to attain proficient acumen in the interpretation and application of PGx findings, given that a significant portion of the adult population of the United Kingdom is prescribed antidepressants, with a notable non-responder percentage13.
Notably, the growing discernment of psychotropic drug-gene interactions accentuates the need for definitive actionability based on pharmacodynamic pharmacogenes13. Enacting structured educational regimes and enforcing standards that oversee the norm of PGx assays are critical in surmounting these encumbrances, thereby unlocking the unmatched potentials of personalized healthcare.
For those interested, in-depth regulatory analyses can be accessed through comprehensive sources like this examination of regulatory frameworks.
The Future of PGx Testing and Personalized Medicine
The vista of pharmacogenomics heralds significant strides in personalized healthcare, with the promise of sophisticated genetic insights. Frontline genomic studies unveil detailed and targeted analyses, delving into the profound relationship between genetic structures and individual drug responses.
Advancements in Genomic Research
The trajectory of genomic exploration foresees a paradigm shift within pharmacogenomics. Eminent examples like the Interprofessional Clinical Pharmacogenomics Certificate, tailored for medical professionals, accentuate the critical nexus between genomic progress and therapeutics for complex conditions such as cardiovascular ailments and oncological challenges14. Complementing this, the Advances in Clinical Pharmacogenomics course at Washington State University offers in-depth studies on the intricate dynamics of gene-environment dialogues and their translation into tailored medical interventions across various illnesses14.
Expansion of PGx Testing Applications
The prevalence of PGx applications is steadily climbing, especially in key fields like oncology, cardiology, and psychiatry. Progressive institutions, including Brigham and Women’s Hospital and Children’s Minnesota, have pioneered the integration of pharmacogenomic specialty units, structured under a two-tiered patient counseling paradigm14. The strategic utilization of a 12-gene pharmacogenetic testing panel, as demonstrated in a European study, has shown remarkable promise by drastically mitigating adverse drug reaction occurrences14. Simultaneously, the progressive cost reduction in PGx testing ushers in the era of preventative genomic analysis, with considerable long-term clinical benefit14.
The surging momentum of genomic research and the institutionalization of pioneering educational initiatives are paramount in driving forward the domain of personalized medicine. As PGx testing’s scope broadens, a critical imperative emerges to remain informed and astutely engage with these advancements to leverage the full potential of pharmacogenomics in enhancing healthcare delivery.
Case Studies: Success Stories in PGx Testing
Pharmacogenomics (PGx) testing has exhibited significant promise in the arena of personalized medicine, particularly within the domains of oncology and cardiology. The narratives within these case studies underscore the pivotal role of PGx testing in fine-tuning therapeutic regimens, thereby enhancing clinical outcomes and mitigating the expanse of healthcare investments.
Oncology: Targeted Cancer Therapies
PGx examination proves highly instrumental in the discernment of genetic markers that prefigure individual reactions to cancer pharmacotherapies, thereby heralding a paradigm shift towards precision and targeted medicinal approaches. Illustrated in an exponent oncology context, the expeditious deployment of PGx analyses notably forestalled substantial prospective Medicare liabilities15. Furthermore, instances of PGx triumphs consistently validate its potential in curbing the polypharmacy burden on patients, effectively diminishing the prevalence of adverse pharmacological interactions whilst enhancing the quality of care delivery15. The expeditious revelation of PGx assay outcomes, often achieved within a mere day or two, incontrovertibly amplifies the therapeutic agility, permitting swift and refined treatment adaptations15.
Cardiology: Optimizing Heart Treatments
In the domain of cardiology, PGx advancements have notched remarkable improvements. By tailoring drug regimens to align with each patient’s genetic blueprint, PGx has substantially bolstered treatment efficacy and safety standards16. This tailored approach, informed by PGx test results, facilitates superior patient outcomes whilst concurrently reducing the quantum of necessary medications, as attested by a plethora of PGx efficacy narratives16. Furthermore, the exposition of the merits of PGx analyses to clinical teams and medical supervisors stands as a critical directive for its seamless integration and perpetuated utilization within clinical practice1516.
Collaborative Efforts in Promoting PGx Testing
The endeavor to promote pharmacogenomics (PGx) testing at both the national and statewide levels encapsulates a significant initiative, necessitating the reciprocal involvement of academia, healthcare institutions, and regulatory organs. These efforts synergize the academic rigor, healthcare proficiency, and regulatory oversight to orchestrate the expansive dissemination and assimilation of PGx testing within clinical contexts.
National and Statewide Initiatives
Illustrative of the nationwide PGx initiatives is the seminal role played by the Clinical Pharmacogenetics Implementation Consortium (CPIC), which has profoundly influenced the pharmacogenomics domain17. Concurrently, the American College of Medical Genetics and Genomics (ACMG) has erected a clinical pharmacogenomic testing and reporting standard, buttressing these endeavors17. Noteworthy efforts, such as the UMN Grand Challenge State-wide Pharmacogenomics Initiative, underscore the significance of regional initiatives in advancing PGx educational and implementational aims, thus demonstrating the substantial influence of localized undertakings on the broader healthcare tapestry.
Interdisciplinary Research and Development
Interdisciplinary research is paramount in advancing the developmental and implementation imperatives of PGx testing. The amalgamation of expertise spanning fields like pharmacy, medicine, bioinformatics, and law is pivotal in pioneering these initiatives17. Essential insights gleaned from studies on preemptive pharmacogenetics implementation schemes in various U.S. healthcare centers underscore the necessity for collaborative, interdisciplinary teamwork to propel PGx testing forward17. Additionally, the U-PGx endeavor furnishes invaluable insights derived from its extensive clinical pharmacogenomic implementation across seven European nations, epitomizing the universal significance and transformative potential of interdisciplinary research in the PGx arena17.
The drive to harmonize these diverse initiatives and research strivings aims to streamline the developmental trajectory of PGx testing within healthcare paradigms. In doing so, it cultivates the milieu necessary for the widespread adoption of personalized medicine.
Understanding the Consumer Perspective
Identifying the importance of the consumer’s viewpoint is fundamental in the seamless incorporation of PGx testing into everyday medical practices. This is echoed by recent research, which signals an upswing in patient cognizance surrounding pharmacogenomics, with a specific focus on the general impression of PGx testing and the benefits it might offer.
Public Awareness and Perception
In a detailed study, it emerged that among a diverse cohort of 45 individuals partaking in a focus group, 67% identified as African-American and 31% as White, collectively manifesting a notably positive stance toward PGx testing18. These findings highlight a keen interest within this cohort due to PGx testing’s capacity to enhance treatment by forecasting individual reactions and mitigating unforeseen drug responses18. Furthermore, the availability of pharmacogenomic data for over 100 medications serves as a testament to the burgeoning understanding and its critical role in the efficacious use of drugs19.
Patient Acceptance and Willingness
The readiness of patients to engage with PGx testing stems from a palpable interest in uncovering personal health risks, refining drug choices, and minimizing the hit-and-miss nature of current treatments18. Noteworthy is the fact that the pilot phase of the RIGHT Protocol enticed a substantive 1013 participants to avail themselves of preemptive PGx testing, indicating both a robust consumer endorsement and community readiness to engage with such initiatives19. Nevertheless, apprehensions surrounding financial implications and insurance coverage loomed large among the study’s respondents18.
The variegated education levels within the focus group’s composition, with 58% boasting at least a Bachelor’s degree, 29% having some college or an associate’s degree, and the remaining 13% indicating a high school diploma or less, point towards a plausible correlation between educational achievements and the grasp of pharmacogenomics, as well as the subsequent inclinations towards and understanding of PGx testing18.
Addressing knowledge gaps via refined educational materials, as demonstrated by a qualitative inquiry on PGx testing, is deemed imperative in fostering broader comprehension and acceptance19.
In conclusion, the impact of patient demographics on their involvement and endorsement of PGx testing is multifaceted, as illustrated below:
| Demographic | Percentage |
|---|---|
| Female | 76% |
| African-American | 67% |
| White | 31% |
| High School Education or Less | 13% |
| Some College or Associate’s Degree | 29% |
| Bachelor’s Degree or Higher | 58% |
| Ages 18-29 | 13% |
| Ages 30-39 | 13% |
| Ages 40-49 | 31% |
| Ages 50-59 | 20% |
| Ages 60-69 | 16% |
| Ages 70 or Older | 5% |
This tabulated data illuminates the diversity of patient backgrounds, shedding light on essential elements that shape public opinion about PGx testing and its potential normative place in healthcare provision.
Conclusion
PGx Testing is precipitating a transformative shift in drug development and clinical trials, directing healthcare towards a patient-centric paradigm. This revolution lies in the nuanced understanding of unique genetic profiles. It enables the refinement of clinical trials, customizing them by discerning the genetic factors influencing drug reactions. Such precision significantly reduces the occurrence of harmful drug responses and boosts the efficiency of medications. Thus, it propels the realization of personalized medicine from a distant aspiration to a near-certainty.
The evolution in pharmacogenomics has erected a critical framework adept at assimilating PGx Testing into the fabric of healthcare. This advancement is supported by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and other key initiatives. With the proliferation of educational campaigns and refined clinical directives, medical professionals are increasingly primed to deploy these tests routinely, improving patient health outcomes. The growing affordability and accessibility of PGx Testing further democratizes its utilization, ensuring its inclusivity across a wider patient demographic.
Consumer inclinations significantly impact the adoption trajectory of PGx Testing. Insight from a focus group comprising mainly female African-Americans who are skewed towards middle age and diverse educational attainments illuminated varying perspectives. While interest in PGx Testing was prevalent, consumer concerns ranged from cost and insurance coverage to the unforeseen disclosure of potential health risks18. Noteworthy, these concerns accentuate the necessity to address the informational, financial, and privacy worries of prospective consumers. This is indispensable for the widespread and effective deployment of PGx Testing.
The future trajectory of PGx Testing is marked by an auspicious outlook, poised for further evolution across medical disciplines. With advancements in technology and the growing competence of healthcare personnel in leveraging pharmacogenomic data, the inclusion of PGx Testing is certain to enhance patient care. This striving towards personalized healthcare promises efficiency and better health outcomes. PGx Testing emerges as a cornerstone in the enhancement of clinical trials, the acceleration of drug innovation, and the establishment of a healthcare system that pivots on individualized therapies.
Source Links
- https://med.umn.edu/pathology/news/mroz-shepherds-pharmacogenomics-pgx-clinic
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514841/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682150/
- https://www.mayo.edu/research/centers-programs/center-individualized-medicine/patient-care/pharmacogenomics/patients
- https://oneome.com/science/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709167/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765968/
- https://www.nature.com/articles/s41525-018-0065-4
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761897/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622662/
- https://www.fightcancer.org/releases/new-paper-finds-barriers-equitable-discovery-and-implementation-pharmacogenomic-testing
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828439/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493030/
- https://pharmacy.wsu.edu/2023/02/10/understanding-the-future-of-pharmacogenomics-testing-in-patient-care/
- https://www.pgxmed.com/pharmacogenetic-testing-pharmacy-consultants-case-study-3/
- http://www.pgxmed.com/category/case-studies/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604616/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306589/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197106/
